226 related articles for article (PubMed ID: 11487306)
21. Residual effects of lovastatin and simvastatin on urinary mevalonate excretions in patients with familial hypercholesterolemia.
Pappu AS; Bacon SP; Illingworth DR
J Lab Clin Med; 2003 Apr; 141(4):250-6. PubMed ID: 12677170
[TBL] [Abstract][Full Text] [Related]
22. Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions.
Mason RP; Walter MF; Day CA; Jacob RF
Am J Cardiol; 2005 Sep; 96(5A):11F-23F. PubMed ID: 16126019
[TBL] [Abstract][Full Text] [Related]
23. Antioxidant effects of statins via S-nitrosylation and activation of thioredoxin in endothelial cells: a novel vasculoprotective function of statins.
Haendeler J; Hoffmann J; Zeiher AM; Dimmeler S
Circulation; 2004 Aug; 110(7):856-61. PubMed ID: 15289372
[TBL] [Abstract][Full Text] [Related]
24. [Anti-inflammatory effect of HMG-CoA reductase inhibitors].
Kitamoto S; Egashira K
Nihon Rinsho; 2004 Jan; 62(1):172-9. PubMed ID: 14737850
[TBL] [Abstract][Full Text] [Related]
25. Clinically relevant pleiotropic effects of statins: drug properties or effects of profound cholesterol reduction?
Comparato C; Altana C; Bellosta S; Baetta R; Paoletti R; Corsini A
Nutr Metab Cardiovasc Dis; 2001 Oct; 11(5):328-43. PubMed ID: 11887430
[TBL] [Abstract][Full Text] [Related]
26. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
27. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors.
Tobert JA
Nat Rev Drug Discov; 2003 Jul; 2(7):517-26. PubMed ID: 12815379
[TBL] [Abstract][Full Text] [Related]
28. Induction of macrophage elastase (MMP-12) gene expression by statins.
Arikan MC; Shapiro SD; Mariani TJ
J Cell Physiol; 2005 Jul; 204(1):139-45. PubMed ID: 15605420
[TBL] [Abstract][Full Text] [Related]
29. A gift from nature: the birth of the statins.
Endo A
Nat Med; 2008 Oct; 14(10):1050-2. PubMed ID: 18841147
[No Abstract] [Full Text] [Related]
30. Drug insight: Immunomodulatory effects of statins--potential benefits for renal patients?
Steffens S; Mach F
Nat Clin Pract Nephrol; 2006 Jul; 2(7):378-87. PubMed ID: 16932466
[TBL] [Abstract][Full Text] [Related]
31. Statins and their role in vascular protection.
Mason JC
Clin Sci (Lond); 2003 Sep; 105(3):251-66. PubMed ID: 12793855
[TBL] [Abstract][Full Text] [Related]
32. Statins and stroke.
Endres M
J Cereb Blood Flow Metab; 2005 Sep; 25(9):1093-110. PubMed ID: 15815580
[TBL] [Abstract][Full Text] [Related]
33. Effects of HMG-CoA reductase inhibitors on endothelial function: role of microdomains and oxidative stress.
Mason RP; Walter MF; Jacob RF
Circulation; 2004 Jun; 109(21 Suppl 1):II34-41. PubMed ID: 15173061
[TBL] [Abstract][Full Text] [Related]
34. Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents?
Schönbeck U; Libby P
Circulation; 2004 Jun; 109(21 Suppl 1):II18-26. PubMed ID: 15173059
[TBL] [Abstract][Full Text] [Related]
35. Essential fatty acids and their metabolites could function as endogenous HMG-CoA reductase and ACE enzyme inhibitors, anti-arrhythmic, anti-hypertensive, anti-atherosclerotic, anti-inflammatory, cytoprotective, and cardioprotective molecules.
Das UN
Lipids Health Dis; 2008 Oct; 7():37. PubMed ID: 18922179
[TBL] [Abstract][Full Text] [Related]
36. [Statins and cardiovascular disease prevention: use and prospective].
Moulin P
Nephrologie; 2000; 21(7):379-80. PubMed ID: 11200617
[No Abstract] [Full Text] [Related]
37. Statins & Alzheimer's.
Feinberg AW
Health News; 2000 Dec; 6(12):1. PubMed ID: 11142934
[No Abstract] [Full Text] [Related]
38. The Role of
Bird JK; Calder PC; Eggersdorfer M
Nutrients; 2018 Jun; 10(6):. PubMed ID: 29914111
[TBL] [Abstract][Full Text] [Related]
39. [Similarities, differences and agonisms of pleiotropic effects of statins and omega-3 fatty acids].
Villalobos ME; Sánchez-Muniz FJ; Acín MT; Vaquero MP; Higueras FJ; Bastida S
Nutr Hosp; 2010; 25(6):889-909. PubMed ID: 21519759
[TBL] [Abstract][Full Text] [Related]
40. 3-Hydroxy-3-methylglutaryl coenzyme a (HMG-CoA) reductase inhibitors (statins), atherosclerosis and coronary syndromes.
Blum A; Simsolo C; Hasin Y
Atherosclerosis; 2004 Jul; 175(1):1-5. PubMed ID: 15186940
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
